Skip to main content
. 2016 Oct 13;78(5):1041–1049. doi: 10.1007/s00280-016-3163-y

Table 2.

Treatment duration of the sVRD regimen

All patients (n = 16)
Completion of 6 courses [n (%)] 16 (100)
Mean treatment duration [courses (range)] 8.0 (6–28)
Reason for discontinuation [n (%)]
 Completion of 6 courses 7 (43.8)
 Disease progression 3 (18.8)
 Second primary malignancy (acute lymphoblastic leukemia) 1 (6.3)
 Adverse events (pneumonia) 1 (6.3)
 Others 4 (25.0)